비인강암의 치료방법에서 Docetaxel과 Platinum을 이용한 유도항암요법의 효과
The Effect of Induction Chemotherapy Using Docetaxel and Platinum in Treatment Methods of Nasopharyngeal Carcinoma
1
조회
0
다운로드
2
인용
0
참고문헌
초록
The aim of this study was to determine the efficacy of induction chemotherapy with docetaxel and platinum in patients with nasopharyngeal carcinoma. Subjects and Method：The medical records of 52 patients, who were diagnosed with NPC at our department from January 1995 to December 2005, were reviewed and retrospectively analyzed. Patients were divided into three groups according to treatment methods. Twenty-eight cases treated with induction chemotherapy consisted of docetaxel, platinum and RT, 17 cases treated with induction chemotherapy consisted of 5-FU, platinum and RT, and 7 cases were treated with RT only. A total of 114 chemotherapy cycles were administered to patients and most received 2 cycles. Results：The T stage distribution at the time of diagnosis was 48%, 14%, 15%, and 23% for T1, T2, T3 and T4, respectively. According to the WHO classification, the type I included 11 cases, type II 2cases, and type III 39 cases. The overall 5-year survival rate was 60.6%. According to the treatment modality, only the RT group was 42.9%. In the chemoradiotherapy group, the 5-year survival rates of 5-FU and platinum combination group and docetaxel and platinum combination group were 47.1% and 78.8%, respectively. There was significant difference in survival (p=0.037). There was no difference in sex, age, and N stage with regards to the 5-year survival rate. Conclusion：Although no valid conclusions could be drawn because of the small number of patients examined in the present study, we found that induction chemotherapy consists of docetaxel and that platinum may improve the outcome of patients with NPC. (Korean J Otorhinolaryngol-Head Neck Surg 2008;51:58-63)
Abstract
The aim of this study was to determine the efficacy of induction chemotherapy with docetaxel and platinum in patients with nasopharyngeal carcinoma. Subjects and Method：The medical records of 52 patients, who were diagnosed with NPC at our department from January 1995 to December 2005, were reviewed and retrospectively analyzed. Patients were divided into three groups according to treatment methods. Twenty-eight cases treated with induction chemotherapy consisted of docetaxel, platinum and RT, 17 cases treated with induction chemotherapy consisted of 5-FU, platinum and RT, and 7 cases were treated with RT only. A total of 114 chemotherapy cycles were administered to patients and most received 2 cycles. Results：The T stage distribution at the time of diagnosis was 48%, 14%, 15%, and 23% for T1, T2, T3 and T4, respectively. According to the WHO classification, the type I included 11 cases, type II 2cases, and type III 39 cases. The overall 5-year survival rate was 60.6%. According to the treatment modality, only the RT group was 42.9%. In the chemoradiotherapy group, the 5-year survival rates of 5-FU and platinum combination group and docetaxel and platinum combination group were 47.1% and 78.8%, respectively. There was significant difference in survival (p=0.037). There was no difference in sex, age, and N stage with regards to the 5-year survival rate. Conclusion：Although no valid conclusions could be drawn because of the small number of patients examined in the present study, we found that induction chemotherapy consists of docetaxel and that platinum may improve the outcome of patients with NPC. (Korean J Otorhinolaryngol-Head Neck Surg 2008;51:58-63)
참고문헌 (15)
- 백승재, "비인강암의 치료 성적과 예후인자 및 치료 실패의 분석", 대한이비인후과학회지 두경부외과학, 48(10), pp.1254~1260 (2005), 대한이비인후과학회
- Cvitkovic E, "Nasopharyngeal carcinoma. Biology, natural history, and therapeutic implications", Hemato Oncol Clin North Am, 5(4), pp.821~838 (1991)
- Choo R, "Chemotherapy for recurrent or metastatic carcinoma of the nasopharyx. A review of the Princess Nargaret Hospital experience", Cancer, 68(10), pp.2120~2124 (1991)
- Decker DA, "Chemotherapy for nasopharyngeal carcinoma. A ten-year experience", Cancer, 52(4), pp.602~605 (1983)
- Colevas AD, "Phase I", II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (op TPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN), 2002, pp.25(2), 153~159
- Janinis J, "Sequential chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced head and neck cancer", Am J Clin Oncol, 24(2), pp.227~231 (2001)
- Posner MR, "Multicenter phase I-II trial of docetaxel, cisplatin and fluorouracil induction chemotherapy for patients with locally advanced squamous cell carcinoma of the head and neck", J Clin Oncol, 19(4), pp.1096~1104 (2001)
- Cooper JS, "Concurrent chemotherapy and radiation therapy for advanced stage carcinoma of the nasopharynx", Int J Radiat Oncol Biol Phys, 48(5), pp.1277~1279 (2000)
- Catimel G, "Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group", Ann Oncol, 5(6), pp.533~537 (1994)
- 임상철, "비인강암에서 방사선치료와 항암화학요법의 병행요법의 예후인자로서의 의의 및 치료성적", 대한이비인후과학회지 두경부외과학, 45(9), pp.897~901 (2002), 대한이비인후과학회
- Altun M, "Undifferentiated nasopharyngeal cancer (UCNT): Current diagnosis and the-rapeutic aspects", Int J Radiat Oncol Biol Phys, 32(3), pp.859~877 (1995)
- Munck JN, "Computed tomographic density of metastatic lymph nodes as a treatment-related prognostic factor in advanced head and neck cancer", J Natl Cancer Inst, 83(8), pp.569~575 (1991)
- Yeo W, "A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma", Eur J Cancer, 34(13), pp.2027~2031 (1998)
- Schöffski P, "Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group", Ann Oncol, 10(1), pp.119~122 (1999)
- Forastiere AA, "Use of paclitaxel (Taxol) in squamous cell carcinoma of the head and neck", Semin Oncol, 20(4), pp.56~60 (1993)